Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders
Neural sleeve first algorithm-powered bionic garment designed to help those with mobility issues due to multiple sclerosis, stroke, cerebral palsy, and other conditions, regain functional movement in everyday activities
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Industry leaders discusses the need of innovation for the Indian drug industry at BioAsia 2022.
The collaboration will accelerate the testing of GliaPharm’s lead molecules in preclinical models of Alzheimer’s disease and further the development of neuroimaging biomarkers
Cataract is the most common cause of blindness in India, and that diabetes is to be blamed for the massive number of damaged eyes
It is used to control, prevent and normalize the symptoms associated with Alzheimer's disease, attention disorder, bipolar disorder, Parkinson's disease among others
he financing was significantly oversubscribed with high demand from both existing and new investors.
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Subscribe To Our Newsletter & Stay Updated
